Subscribe To

Price Alert Latest News Economic Calendar News

TSVT / 2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting

2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced the presentation of five abstracts, including one late-breaking oral presentation, at this year's American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, California from May 16-20, 2023. The late-breaking abstract featuring early findings from the ongoing Phase 1 PLAT-08 trial in collaboration with Seattle Children's Thera. Read More

Demo Live Account See Partner Details

Content Topics

2seventy

Present

Preclinical

Clinical

Data

From

Broad

Portfolio

Investigational

Therapies

Annual

Meeting

Stock

TSVT

Posted: May 2 2023, 16:37

Author Name: Business Wire

TSVT News

By Zacks Investment Research
September 13, 2023

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collab

By Reuters
September 12, 2023

2seventy bio to lay off 40% of workforce

2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.

By Seeking Alpha
June 21, 2023

2seventy bio: Nothing Properly Explains The Low Valuation

By Zacks Investment Research
June 15, 2023

2seventy (TSVT) Down 9% on Patient Death in Leukemia Study

Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is st

By Seeking Alpha
May 6, 2023

2seventy bio, Inc. (TSVT) Q1 2023 Earnings Call Transcript

2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM ET Company Participants Jenn Snyder - SVP of Corporate Affairs

By Zacks Investment Research
May 3, 2023

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

2seventy bio, Inc. (TSVT) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to l

By Business Wire
May 2, 2023

2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced the presentation

By Zacks Investment Research
March 16, 2023

2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the nu

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.